Biotech shares eviscerated in wake of Covid-19 flop

Amber Tong

When Southampton, UK-based Synairgen last updated its investors, CEO Richard Marsden spotlighted the progress it’s making on the Phase III SPRINTER trial for the lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech shares eviscerated in wake of Covid-19 flop

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Lilly pays $10M upfront for Organovo’s FXR agonist program

Compounders sue FDA over removal of semaglutide from official shortage list

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry

Biotech shares evis­cer­at­ed in wake of Covid-19 flop

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Biotech shares eviscerated in wake of Covid-19 flop